Northern Trust Corp Buys 68,174 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Northern Trust Corp grew its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,314,871 shares of the biopharmaceutical company's stock after purchasing an additional 68,174 shares during the quarter. Northern Trust Corp owned approximately 0.84% of Ocular Therapeutix worth $11,229,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Ocular Therapeutix by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after purchasing an additional 99,730 shares during the last quarter. Deltec Asset Management LLC boosted its holdings in Ocular Therapeutix by 0.6% in the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock valued at $22,344,000 after purchasing an additional 16,300 shares during the period. Artisan Partners Limited Partnership grew its holdings in shares of Ocular Therapeutix by 26.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock worth $11,398,000 after purchasing an additional 278,610 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Ocular Therapeutix by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company's stock valued at $9,663,000 after purchasing an additional 21,025 shares in the last quarter. Finally, Rosalind Advisors Inc. boosted its stake in shares of Ocular Therapeutix by 27.5% in the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after purchasing an additional 243,700 shares in the last quarter. 59.21% of the stock is owned by institutional investors.

Ocular Therapeutix Stock Performance

Shares of Ocular Therapeutix stock traded up $0.09 during trading hours on Tuesday, hitting $7.60. 1,201,407 shares of the company were exchanged, compared to its average volume of 1,399,901. Ocular Therapeutix, Inc. has a 1 year low of $4.79 and a 1 year high of $11.78. The business has a 50-day moving average of $7.39 and a 200-day moving average of $8.10. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -5.76 and a beta of 1.51. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. As a group, analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Royal Bank of Canada began coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 target price for the company. William Blair initiated coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an "outperform" rating on the stock. Needham & Company LLC cut their target price on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, HC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $16.25.

Insiders Place Their Bets

In related news, Director Richard L. Md Lindstrom acquired 10,000 shares of the business's stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average cost of $6.96 per share, with a total value of $69,600.00. Following the purchase, the director now owns 172,704 shares of the company's stock, valued at approximately $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the company's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. This trade represents a 0.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.30% of the stock is currently owned by corporate insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.